1.Effects of function-oriented training on the balance of stroke survivors and their ability in the activities of daily living
Minya ZHOU ; Kunqiang YU ; Lixiu WU ; Shufang LIN ; Ruhui LIN
Chinese Journal of Physical Medicine and Rehabilitation 2021;43(4):327-331
Objective:To observe any effect of function-oriented training on the balance of recovering stroke survivors and on their ability in the activities of daily living.Methods:Sixty stroke survivors in recovery were randomly divided into an observation group ( n=30) and a control group ( n=30). The control group received routine rehabilitation training, while the observation group underwent function-oriented training for 6 weeks. Before and after the intervention, both groups were evaluated using the Berg balance scale (BBS), the Fugl-Meyer lower extremity assessment (FMA-L), the timed up-and-go test (TUGT) and the modified Barthel index (MBI). Results:After the treatment, significant improvement was observed in all of the measurements in both groups. The improvements in the average BBS, FMA-L and MBI scores and in the TUGT times of the observation group were significantly better than those of the control group.Conclusion:Function-oriented training can improve the balance and the ability in the activities of daily living of stroke survivors more effectively than the routine therapy.
2.Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors.
Minya LU ; Li ZHANG ; Yue LI ; Hanping WANG ; Xiaoxiao GUO ; Jiaxin ZHOU ; Lian DUAN ; Xiaoyan SI ; Yingchun XU ; Li ZHANG
Chinese Journal of Lung Cancer 2019;22(10):666-670
Immune checkpoint inhibitors (ICIs) have been widely used in management of malignant tumor. Programmed death ligand 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune-related adverse events (irAEs) that can require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there were reports about reactivation of chronic/latent infections without irAEs. Thus, immune checkpoint inhibitor related infections have drawn more and more attention in the world. In this paper, we described the potential mechanism, available clinical data and recommendation of diagnosis and management for PD-1/PD-L1 inhibitor related infections.